ANI Pharmaceuticals 2022 H.C. Wainwright Bioconnect Conference

ANI Pharmaceuticals presented at the January 2022 H.C. Wainwright Bioconnect Conference, highlighting its diversified biopharmaceutical portfolio spanning rare disease, generics, established brands, and CDMO businesses. The company showcased its transformational Cortrophin Gel opportunity following FDA approval in October 2021, targeting a $770M ACTH market, alongside a proven track record of strategic acquisitions and sustainable growth.